Plasmacytoma
Symptoms, Doctors, Treatments, Advances & More

Plasmacytoma Overview

Save information for later
Sign Up

Learn About Plasmacytoma

Who are the top Plasmacytoma Local Doctors?
Elite in Plasmacytoma
Elite in Plasmacytoma
Referral may be required

Office

1515 Holcombe Blvd Unit 429, 
Houston, TX 
713-792-3510
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Orlowski is an Oncologist practicing medicine in Houston, Texas. Dr. Orlowski is rated as an Elite provider by MediFind in the treatment of Plasmacytoma. He is also highly rated in 10 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Plasmacytoma, Smoldering Multiple Myeloma, Endometrial Cancer, and Bone Marrow Aspiration.

Elite in Plasmacytoma
Elite in Plasmacytoma
Referral may be required
Head And Neck, 
Nantes, FR 

Philippe Moreau practices practicing medicine in Nantes, France. Mr. Moreau is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. He is also highly rated in 20 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Plasmacytoma
Elite in Plasmacytoma
Referral may be required
Paris, FR 

Youlia Kirova practices practicing medicine in Paris, France. Kirova is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. They are also highly rated in 14 other conditions, according to our data. Their clinical expertise encompasses Breast Cancer, Plasmacytoma, Mediastinal Tumor, Mastectomy, and Bone Marrow Aspiration.

View All Doctors
What are the latest Plasmacytoma Clinical Trials?
Clinical Study of CD123 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory Acute Myeloid Leukemia (AML)or Blastic Plasmacytoid Dendritic Cell Neoplasm(BPDCN)
Clinical Study of CD123 Targeting Chimeric Antigen Receptor NK Cells (CAR-NK) in the Treatment of Relapse/Refractory Acute Myeloid Leukemia (AML)or Blastic Plasmacytoid Dendritic Cell Neoplasm(BPDCN)
Enrollment Status: Recruiting
Publish Date: August 28, 2026
Intervention Type: Drug
Study Phase: Phase 1

Summary: This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD123 CAR-NK in the treatment of patients with relapsed/refractory acute myeloid leukemia or blastic plasma cell like dendritic cell tumors.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Who is this study for: Patients with relapsed/refractory hematological malignances
Enrollment Status: Recruiting
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
Study Phase: Phase 1/Phase 2

Summary: The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center